RUDI VAN DEN EYNDE, Head of Thematic Global Equity, & SERVAAS MICHIELSSENS, Senior Biotechnology Analyst at Candriam, outline to investors the approach they have used to create & develop an investment strategy in the oncology sector.
We use cookies to offer useful features and measure performance to improve your experience. By clicking “Accept all” you agree to the use of all cookies. By clicking “Accept selected”, you agree only to the categories you have selected. You can find further information in our Privacy Policy.
These cookies are necessary for our website to work properly, so that you use the most important functions and navigate smoothly. This includes essential security and accessibility features, and preferences you select such as interface and translator language.
Performance
Cookies that measure how our site is used. We use this information to improve our website and services. With these cookies we measure, for example, how often users return and which functions they use.
Confort
These cookies enable the website to provide enhanced functionality and personalisation. For example, remembering which pages you visited and personalise your experience based on this.
Topics
Highlighted
Authors
Resources
Article 173
SFDR
RUDI VAN DEN EYNDE, Head of Thematic Global Equity, & SERVAAS MICHIELSSENS, Senior Biotechnology Analyst at Candriam, outline to investors the approach they have used to create & develop an investment strategy in the oncology sector.